TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:57
Anixa Biosciences Inc ( ANIX ) https://www.anixa.com
2.57USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-33.93%
ANIX
SPY
32.66%
-10.76%
ANIX
SPY
108.59%
-11.07%
ANIX
SPY
302.52%
ANIX
1.28%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
86.23
65.72
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.98
0.03
4.17
0.00
0.00
-4.62
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2313.46
-8.33
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.816
-272.71
-56.09
0.95
Other Earnings and Cash Flow Stats:
Anixa Biosciences Inc ( ANIX ) Net Income TTM ($MM) is -12.36
Anixa Biosciences Inc ( ANIX ) Operating Income TTM ($MM) is -13.72
Anixa Biosciences Inc ( ANIX ) Owners' Earnings Annual ($MM) is 0.00
Anixa Biosciences Inc ( ANIX ) Current Price to Owners' Earnings ratio is 0.00
Anixa Biosciences Inc ( ANIX ) EBITDA TTM ($MM) is -13.68
Anixa Biosciences Inc ( ANIX ) EBITDA Margin is 0.00%
Capital Allocation:
Anixa Biosciences Inc ( ANIX ) has paid 0.00 dividends per share and bought back -1.074 million shares in the past 12 months
Anixa Biosciences Inc ( ANIX ) has increased its debt by 0.062 million USD in the last 12 months
Capital Structure:
Anixa Biosciences Inc ( ANIX ) Interest-bearing Debt ($MM) as of last quarter is 0
Anixa Biosciences Inc ( ANIX ) Annual Working Capital Investments ($MM) are 0
Anixa Biosciences Inc ( ANIX ) Book Value ($MM) as of last quarter is 20
Anixa Biosciences Inc ( ANIX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Anixa Biosciences Inc ( ANIX ) has 1 million in cash on hand as of last quarter
Anixa Biosciences Inc ( ANIX ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Anixa Biosciences Inc ( ANIX ) has 32 common shares outstanding as of last quarter
Anixa Biosciences Inc ( ANIX ) has 0 million USD of preferred stock value
Academic Scores:
Anixa Biosciences Inc ( ANIX ) Altman Z-Score is 7.83 as of last quarter
Anixa Biosciences Inc ( ANIX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Anixa Biosciences Inc ( ANIX ) largest shareholder is Tower Research Capital LLC (TRC) owning 1483 shares at 0.00 ($MM) value
Titterton Lewis H jr(an insider) Bought 5580 shares of Anixa Biosciences Inc ( ANIX ) for the amount of $18023.40 on 2024-07-31
5.05% of Anixa Biosciences Inc ( ANIX ) is held by insiders, and 17.46% is held by institutions
Anixa Biosciences Inc ( ANIX ) went public on 1987-01-01
Other Anixa Biosciences Inc ( ANIX ) financial metrics:
FCF:-8.38
Unlevered Free Cash Flow:0.00
EPS:-0.41
Operating Margin:-2313.46
Gross Profit Margin:-8.33
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-60.21
Beta:0.95
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Anixa Biosciences Inc ( ANIX ) :
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.